Editorials
SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity
Read
1311
Timeswas read the article
409
Total PDF
902
Total HTML
Share statistics
array:23 [ "pii" => "S1807593222012315" "issn" => "18075932" "doi" => "10.1016/j.clinsp.2022.100057" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100057" "copyright" => "HCFMUSP" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Clinics. 2022;77C:" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S1807593222033221" "issn" => "18075932" "doi" => "10.1016/j.clinsp.2022.100121" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100121" "copyright" => "HCFMUSP" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Clinics. 2022;77C:" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorials</span>" "titulo" => "Sex differences in Parkinson's Disease: An emerging health question" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luiz Philipe de Souza Ferreira, Rafael André da Silva, Matheus Marques Mesquita da Costa, Vinicius Moraes de Paiva Roda, Santiago Vizcaino, Nilma R.L.L. Janisset, Renata Ramos Vieira, José Marcos Sanches, José Maria Soares Junior, Manuel de Jesus Simões" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Luiz" "apellidos" => "Philipe de Souza Ferreira" ] 1 => array:2 [ "nombre" => "Rafael" "apellidos" => "André da Silva" ] 2 => array:2 [ "nombre" => "Matheus" "apellidos" => "Marques Mesquita da Costa" ] 3 => array:2 [ "nombre" => "Vinicius" "apellidos" => "Moraes de Paiva Roda" ] 4 => array:2 [ "nombre" => "Santiago" "apellidos" => "Vizcaino" ] 5 => array:2 [ "nombre" => "Nilma R.L.L." "apellidos" => "Janisset" ] 6 => array:2 [ "nombre" => "Renata" "apellidos" => "Ramos Vieira" ] 7 => array:2 [ "nombre" => "José" "apellidos" => "Marcos Sanches" ] 8 => array:2 [ "nombre" => "José" "apellidos" => "Maria Soares Junior" ] 9 => array:2 [ "nombre" => "Manuel" "apellidos" => "de Jesus Simões" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222033221?idApp=UINPBA00004N" "url" => "/18075932/000000770000000C/v3_202308251443/S1807593222033221/v3_202308251443/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S180759322200031X" "issn" => "18075932" "doi" => "10.1016/j.clinsp.2022.100035" "estado" => "S300" "fechaPublicacion" => "2022-01-01" "aid" => "100035" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Clinics. 2022;77C:" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "The right to vaccination and the individual duty in collective health during a pandemic" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juliana Bertoldi Franco, Pilar Lecussan Gutierrez, Fábio Roberto Cabar, Chin An Lin" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Juliana" "apellidos" => "Bertoldi Franco" ] 1 => array:2 [ "nombre" => "Pilar" "apellidos" => "Lecussan Gutierrez" ] 2 => array:2 [ "nombre" => "Fábio Roberto" "apellidos" => "Cabar" ] 3 => array:2 [ "nombre" => "Chin" "apellidos" => "An Lin" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S180759322200031X?idApp=UINPBA00004N" "url" => "/18075932/000000770000000C/v3_202308251443/S180759322200031X/v3_202308251443/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorials</span>" "titulo" => "SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Amanda Izeli Portilho, Gabrielle Gimenes Lima, Elizabeth De Gaspari" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Amanda Izeli" "apellidos" => "Portilho" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0002" ] ] ] 1 => array:3 [ "nombre" => "Gabrielle Gimenes" "apellidos" => "Lima" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0002" ] ] ] 2 => array:4 [ "nombre" => "Elizabeth" "apellidos" => "De Gaspari" "email" => array:1 [ 0 => "elizabeth.gaspari@ial.sp.gov.br" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0002" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0001" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Departament of Immunology, Adolfo Lutz Institute, São Paulo, SP, Brazil" "etiqueta" => "a" "identificador" => "aff0001" ] 1 => array:3 [ "entidad" => "Gradute Program Interunits in Biotechnology, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP, Brazil" "etiqueta" => "b" "identificador" => "aff0002" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0001" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Departament of Immunology, Adolfo Lutz Institute. Av Dr Arnaldo, 355, Cerqueira César, São Paulo, SP 01246-902, Brazil, Tel.: +55 11 30682898." ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0001">Introduction</span><p id="para0001" class="elsevierStylePara elsevierViewall">The presence of IgA antibodies at the beginning of infection by SARS-CoV-2 and in various locations, such as the blood, Bronchoalveolar Lavage (BAL), and saliva, demand attention, as well as its correlation with neutralizing antibodies. The early IgA appearance was recently described in very well-conducted research by Sterlin et al.<a class="elsevierStyleCrossRef" href="#bib0001"><span class="elsevierStyleSup">1</span></a></p><p id="para0002" class="elsevierStylePara elsevierViewall">With the emergence of SARS-CoV-2 variants, there are chances that COVID-19 vaccines will have to be further improved. The authors’ comprehension of immunity against SARS-CoV-2 should pave the way for the vaccine's refinement. Herein, the authors briefly discuss the issues related to this matter.</p></span><span id="sec0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0002">Mucosal immunization</span><p id="para0003" class="elsevierStylePara elsevierViewall">When the authors think about intranasal immunization, it comes to mind the story of the first Intranasal (IN) vaccination, documented in a Chinese medicine text, in the year 1742. It consisted of an attempt at immunization against variola. However, only in 2000 the first IN vaccine was approved for use in humans, in the United States: the FluMist® vaccine (AstraZeneca), against Influenza. The development of this vaccine led to investments in research related to the area.<a class="elsevierStyleCrossRef" href="#bib0002"><span class="elsevierStyleSup">2</span></a></p><p id="para0004" class="elsevierStylePara elsevierViewall">Despite several reports currently described in the literature on the advantages of intranasal vaccination, a worrying aspect of this immunization pathway was the association established between the vaccination with an inactivated influenza virus vaccine adjuvanted by the heat-labile toxin of <span class="elsevierStyleItalic">Escherichia coli</span> and Bell's Palsy, a facial nerve paralysis, in 2002‒2003.<a class="elsevierStyleCrossRef" href="#bib0003"><span class="elsevierStyleSup">3</span></a> After this episode, it became clear that the IN delivery of vaccines should consider the anatomical proximity between the nasal cavity and the central nervous system. To increase their safety, such vaccines should use suitable adjuvants and transport systems, thus avoiding their deposition in the nervous system.<a class="elsevierStyleCrossRef" href="#bib0004"><span class="elsevierStyleSup">4</span></a></p><p id="para0005" class="elsevierStylePara elsevierViewall">Other points to discuss to the IN vaccines are related to the manufacturing and distribution, such as transport, adjuvant, vector, and dosage, not only the immune responses induced.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">5</span></a> Even in the current moment, where safe IN vaccines would benefit the control of COVID-19 pandemics, the authors have to be aware of its issues, especially the adjuvant use or delivery systems needed, as described above. As the authors know, it is not very easy for government agencies and non-profit organizations worldwide to support the commercialization of these technologies, thus leading to rapid mass vaccination.<a class="elsevierStyleCrossRef" href="#bib0006"><span class="elsevierStyleSup">6</span></a> Thus, adjuvants and delivery systems can increase the cost of vaccines, making it even more difficult to expand vaccine coverage by IN formulations. Considering the moment that the world is going through, the scientific community cannot focus only on pointing out deficiencies, but also on putting effort to find solutions in a short time.</p></span><span id="sec0003" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0003">Protective potential: variants of concern (VOCs) and avidity</span><p id="para0006" class="elsevierStylePara elsevierViewall">Recently, the authors observed an increase in cases caused by the Omicron variant. Most vaccines use the Spike protein as antigen and several VOCs present mutations in this antigen to increase affinity towards ACE2 receptor.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0007"><span class="elsevierStyleSup">7</span></a> Therefore, the next SARS-CoV-2 vaccines should be refined to address this issue, protecting against VOCs and preventing new COVID-19 waves.</p><p id="para0007" class="elsevierStylePara elsevierViewall">It is known that the longer the active infection, the higher the chance of VOCs arising. So, the activation of mucosal immunity would be interesting to limit the viral spread in the upper respiratory tract.<a class="elsevierStyleCrossRef" href="#bib0008"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0009"><span class="elsevierStyleSup">9</span></a> With an earlier control of the infection, which could be provided by adequate mucosal immunity, it is less likely for SARS-CoV-2 to rearrange and mutate.</p><p id="para0008" class="elsevierStylePara elsevierViewall">Another point is the functionality of antibodies. The importance of the affinity maturation of humoral response has been discussed.<a class="elsevierStyleCrossRef" href="#bib0007"><span class="elsevierStyleSup">7</span></a> There is evidence that natural infection does not provide high avidity antibodies, which would fail in controlling the disease. On the other hand, vaccination has induced antibodies with higher avidity indexes, favoring the maturation of the immune response.<a class="elsevierStyleCrossRef" href="#bib0007"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">10</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0011"><span class="elsevierStyleSup">11</span></a> All that points out that the avidity of antibodies must be observed for adequate vaccines.<a class="elsevierStyleCrossRef" href="#bib0007"><span class="elsevierStyleSup">7</span></a></p><p id="para0009" class="elsevierStylePara elsevierViewall">The avidity of mucosal IgA had not been studied extensively like IgG, making it harder to point out its role in preventing COVID-19.<a class="elsevierStyleCrossRef" href="#bib0012"><span class="elsevierStyleSup">12</span></a> However, a study comparing the systemic IgA, IgM, and IgG response of COVID-19 patients to Spike pre-fusion epitope found increased avidity of recovered compared to deceased patients.<a class="elsevierStyleCrossRef" href="#bib0013"><span class="elsevierStyleSup">13</span></a> Another investigation, which employed both serum and nasal wash samples verified a higher affinity of asymptomatic compared to symptomatic patients.<a class="elsevierStyleCrossRef" href="#bib0014"><span class="elsevierStyleSup">14</span></a> Such results suggest that IgA avidity might improve the outcome of natural infection. The authors assume that the somatic mutations of mucosal plasma cells and IgA affinity are promising fields of study, which would support vaccine refinements as well.</p></span><span id="sec0004" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0004">Vaccines beyond pathogen-specific prevention</span><p id="para0010" class="elsevierStylePara elsevierViewall">Many reports described in the literature suggest that vaccines may have not only specific effects on the disease but on other infections. When Vaccinia, the first human vaccine, was introduced in the early 19th century, it was noticed an heterologous protection from various atopic diseases, such as measles, scarlet fever, and syphilis, aside from smallpox. When the Calmette-Guérin (BCG) bacillus vaccine was used in Sweden, mortality was almost 3 times lower among vaccinated children. As the main reduction in mortality occurs in childhood, it cannot be 100% explained by the prevention of tuberculosis, which killed mainly older children. Another relevant point to be investigated suggests stimulation with the nonspecific BCG vaccine another point to think about.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">15</span></a></p><p id="para0011" class="elsevierStylePara elsevierViewall">There are not many studies in the literature on nonspecific immunity, which mostly suggest the engagement of B and T-cells and indicates a non-specific immune memory. There are also reports associating the participation of macrophages and Natural Killer (NK) cells. In addition, the participation of innate immunity involves epigenetic programming. It is safe to suppose that both innate and adaptive mechanisms take part in this cross-reactive immunity, given that the arms of the immune response are built to complement each other. This aspect, discussed as trained immunity, could generate a new understanding of immunological data related to vaccines and could thus impact resistance and general protection to the disease.<a class="elsevierStyleCrossRef" href="#bib0016"><span class="elsevierStyleSup">16</span></a></p><p id="para0012" class="elsevierStylePara elsevierViewall">The authors recall an example described in the literature that correlates immune system training related to the latency of the Herpes virus, which seems to protect against bacterial infection. That would happen through systemic activation of macrophages and production of IFN-γ, thus leading authors to suggest that herpes viruses are symbionts, rather than pathogens, in humans.<a class="elsevierStyleCrossRef" href="#bib0017"><span class="elsevierStyleSup">17</span></a> It is important to think that the picture in which the innate immune system is characterized by adaptive features and can be trained to provide partial protection against infection independent of the classical T and B cell adaptive immunity deserves further studies.<a class="elsevierStyleCrossRef" href="#bib0018"><span class="elsevierStyleSup">18</span></a></p></span><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0005">Adequacy of SARS-CoV-2 vaccines</span><p id="para0013" class="elsevierStylePara elsevierViewall">In the recent paper, Gaspar and De Gaspari<a class="elsevierStyleCrossRef" href="#bib0019"><span class="elsevierStyleSup">19</span></a> observed Neutralizing antibodies to SARS-CoV-2 after IN administration of recombinant RBD. These experimental studies simulated the entry of the pathogen through the nasal route. The proposed platform using <span class="elsevierStyleItalic">Neisseria meningitidis</span> Outer Membrane Vesicles (OMVs) as adjuvant appears to be an alternative platform for a vaccine that stimulates different compartments of the immune system, culminating with the production of IgA antibodies soon after an IN dose of the antigen. Hence, outer membrane vesicles are technically easy and cheap to obtain, as an example of affordable adjuvants to improve vaccine manufacturing.</p><p id="para0014" class="elsevierStylePara elsevierViewall">Another interesting point for investigation is the lymphatic drainages of the parental sites of immunization, due to the targeting of particular lymphoid inductive sites. Some of these sites may represent the crossroads between systemic and mucosal immunity.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">20</span></a> Thus, there is suggestive evidence that mucosal immunization can induce seric IgA because of B cells homing to the marginal zone of the spleen after activation at the mucosa.<a class="elsevierStyleCrossRef" href="#bib0021"><span class="elsevierStyleSup">21</span></a> Considering the potential role of IgA to control COVID-19, these are aspects that are worthy of studying.</p><p id="para0015" class="elsevierStylePara elsevierViewall">Although the authors managed to develop effective vaccines that have diminished the COVID-19 burden in different parts of the world,<a class="elsevierStyleCrossRef" href="#bib0022"><span class="elsevierStyleSup">22</span></a> it is still relevant to evaluate different platforms including the use of different adjuvants, mucosa stimulation, and the key immunological compartments to be activated.<a class="elsevierStyleCrossRef" href="#bib0023"><span class="elsevierStyleSup">23</span></a></p></span><span id="sec0005a" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0005a">CRediT authorship contribution statement</span><p id="para0015a" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Amanda Izeli Portilho:</span> Writing – review & editing, Writing – original draft. <span class="elsevierStyleBold">Gabrielle Gimenes Lima:</span> Writing – review & editing, Writing – original draft. <span class="elsevierStyleBold">Elizabeth De Gaspari:</span> Conceptualization, Writing – review & editing, Writing – original draft.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0001" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "sec0002" "titulo" => "Mucosal immunization" ] 2 => array:2 [ "identificador" => "sec0003" "titulo" => "Protective potential: variants of concern (VOCs) and avidity" ] 3 => array:2 [ "identificador" => "sec0004" "titulo" => "Vaccines beyond pathogen-specific prevention" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Adequacy of SARS-CoV-2 vaccines" ] 5 => array:2 [ "identificador" => "sec0005a" "titulo" => "CRediT authorship contribution statement" ] 6 => array:2 [ "identificador" => "xack684966" "titulo" => "Acknowledgments" ] 7 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-02-08" "fechaAceptado" => "2022-05-23" "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec1" "bibliografiaReferencia" => array:23 [ 0 => array:3 [ "identificador" => "bib0001" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IgA dominates the early neutralizing antibody response to SARS-CoV-2" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Sterlin" 1 => "A. Mathian" 2 => "M. Miyara" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Sci Transl Med" "fecha" => "2021" "volumen" => "20" "numero" => "577" "paginaInicial" => "eabd2223" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0002" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The evolution of nasal immune systems in vertebrates" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Sepahi" 1 => "I. Salinas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.molimm.2015.09.008" "Revista" => array:6 [ "tituloSerie" => "Mol Immunol" "fecha" => "2016" "volumen" => "69" "paginaInicial" => "131" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26391349" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0003" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of the inactivated intranasal influenza vaccine and the risk of Bell's Palsy in Switzerland" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Mutsch" 1 => "W. Zhou" 2 => "P. Rhodes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa030595" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "350" "numero" => "9" "paginaInicial" => "896" "paginaFinal" => "903" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14985487" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0004" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NALT- versus Peyer's-patch-mediated mucosal immunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Kiyono" 1 => "S. Fukuyama" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nri1439" "Revista" => array:7 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2004" "volumen" => "4" "numero" => "9" "paginaInicial" => "699" "paginaFinal" => "710" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15343369" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0005" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SARS-CoV-2 vaccines in development" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Krammer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41586-020-2798-3" "Revista" => array:7 [ "tituloSerie" => "Nature" "fecha" => "2020" "volumen" => "586" "numero" => "7830" "paginaInicial" => "516" "paginaFinal" => "527" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32967006" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0006" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The dream vaccine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Cohen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/science.372.6539.227" "Revista" => array:7 [ "tituloSerie" => "Science" "fecha" => "2021" "volumen" => "372" "numero" => "6539" "paginaInicial" => "227" "paginaFinal" => "231" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33859017" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0007" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G. Bauer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Explor Immonol" "fecha" => "2022" "volumen" => "2" "paginaInicial" => "133" "paginaFinal" => "156" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0008" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "O. Gallo" 1 => "L.G. Locatello" 2 => "A. Mazzoni" 3 => "L. Novelli" 4 => "F. Annunziato" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41385-020-00359-2" "Revista" => array:7 [ "tituloSerie" => "Mucosal Immunol" "fecha" => "2021" "volumen" => "14" "numero" => "2" "paginaInicial" => "305" "paginaFinal" => "316" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33244161" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0009" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The germinal centre B cell response to SARS-CoV-2" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B.J. Laidlow" 1 => "A.H. Ellebedy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41577-021-00657-1" "Revista" => array:7 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2022" "volumen" => "22" "numero" => "1" "paginaInicial" => "7" "paginaFinal" => "18" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34873279" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0010" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A.D. Moura" 1 => "H.H.M. Costa" 2 => "V.A. Correa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41598-021-95045-z" "Revista" => array:5 [ "tituloSerie" => "Sci Rep" "fecha" => "2021" "volumen" => "11" "paginaInicial" => "17642" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34480056" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0011" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vaccination <span class="elsevierStyleItalic">versus</span> infection with SARS-CoV-2: establishment of a high avidity IgG response <span class="elsevierStyleItalic">versus</span> incomplete avidity maturation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F. Struck" 1 => "P. Schreiner" 2 => "E. Staschik" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.27270" "Revista" => array:7 [ "tituloSerie" => "J Med Virol" "fecha" => "2021" "volumen" => "93" "numero" => "12" "paginaInicial" => "6765" "paginaFinal" => "6777" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34387884" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0012" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IgA and the intestinal microbiota: the importance of being specific" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "O. Pabst" 1 => "E. Slack" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Mucosal Immunol" "fecha" => "2020" "volumen" => "13" "numero" => "1" "paginaInicial" => "12" "paginaFinal" => "21" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0013" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Tang" 1 => "S. Ravichandran" 2 => "Y. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41467-021-21463-2" "Revista" => array:6 [ "tituloSerie" => "Nat Commun" "fecha" => "2021" "volumen" => "12" "numero" => "1" "paginaInicial" => "1221" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33619281" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0014" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2 – infected individuals reveal unlinked immune signatures" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Ravichandran" 1 => "G. Grubbs" 2 => "J.J. Tang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/sciadv.abi6533" "Revista" => array:6 [ "tituloSerie" => "Sci Adv" "fecha" => "2021" "volumen" => "7" "numero" => "42" "paginaInicial" => "eabi6533" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34644111" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0015" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971–2010" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Rieckmann" 1 => "M. Villumsem" 2 => "S. Sørup" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ije/dyw120" "Revista" => array:7 [ "tituloSerie" => "Int J Epidemiol" "fecha" => "2017" "volumen" => "46" "numero" => "2" "paginaInicial" => "695" "paginaFinal" => "705" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27380797" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0016" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Defining trained immunity and its role in health and disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.G. Netea" 1 => "J. Dominguéz-Andréz" 2 => "L.B. Barreiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41577-020-0285-6" "Revista" => array:7 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2020" "volumen" => "20" "numero" => "6" "paginaInicial" => "375" "paginaFinal" => "388" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32132681" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0017" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Herpesvirus latency confers symbiotic protection from bacterial infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.S. Barton" 1 => "D.W. White" 2 => "J.S. Cathelyn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nature05762" "Revista" => array:7 [ "tituloSerie" => "Nature" "fecha" => "2007" "volumen" => "447" "numero" => "7142" "paginaInicial" => "326" "paginaFinal" => "329" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17507983" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0018" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A small jab ‒ a big effect: nonspecific immunomodulation by vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C.S. Benn" 1 => "M.G. Netea" 2 => "L.K. Selin" 3 => "P. Aaby" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.it.2013.04.004" "Revista" => array:7 [ "tituloSerie" => "Trends Immunol" "fecha" => "2013" "volumen" => "34" "numero" => "9" "paginaInicial" => "431" "paginaFinal" => "439" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23680130" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0019" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Avidity assay to test functionality of anti-SARS-Cov-2 antibodies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.B. Gaspar" 1 => "E. De Gaspari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2021.02.003" "Revista" => array:7 [ "tituloSerie" => "Vaccine" "fecha" => "2021" "volumen" => "39" "numero" => "10" "paginaInicial" => "1473" "paginaFinal" => "1475" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33581919" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0020" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "B. Guy" 1 => "S. Fourage" 2 => "C. Hessler" 3 => "V. Sanchez" 4 => "M.J. Millet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CDLI.5.5.732-736.1998" "Revista" => array:7 [ "tituloSerie" => "Clin Diagn Lab Immunol" "fecha" => "1998" "volumen" => "5" "numero" => "5" "paginaInicial" => "732" "paginaFinal" => "736" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9729544" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0021" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A role for gut-associated lymphoid tissue in shaping the human B cell repertoire" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Vossenkamper" 1 => "P.A. Blair" 2 => "N. Safinia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1084/jem.20122465" "Revista" => array:7 [ "tituloSerie" => "J Exp Med" "fecha" => "2013" "volumen" => "210" "numero" => "9" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23940259" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0022" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "World Health Organization. COVID-19 vaccines. <a target="_blank" href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines</a>." ] ] ] 22 => array:3 [ "identificador" => "bib0023" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E.B. Gaspar" 1 => "C.R. Prudencio" 2 => "E. De Gaspari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/21645515.2021.1920272" "Revista" => array:7 [ "tituloSerie" => "Hum Vaccin Immunother" "fecha" => "2021" "volumen" => "17" "numero" => "9" "paginaInicial" => "2965" "paginaFinal" => "2968" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33950776" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack684966" "titulo" => "Acknowledgments" "texto" => "<p id="para0017" class="elsevierStylePara elsevierViewall">Fundação de Amparo à Pesquisa do Estado de São Paulo [FAPESP], under grants numbers 12/15568 and 18/04202-0, Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq], under grants number 131412/2019-1 and 131308/2021-1 and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [CAPES], finance code 001.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/18075932/000000770000000C/v3_202308251443/S1807593222012315/v3_202308251443/en/main.assets" "Apartado" => array:4 [ "identificador" => "94922" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorials" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/18075932/000000770000000C/v3_202308251443/S1807593222012315/v3_202308251443/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222012315?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 1 | 7 |
| 2024 October | 40 | 29 | 69 |
| 2024 September | 42 | 29 | 71 |
| 2024 August | 55 | 22 | 77 |
| 2024 July | 51 | 14 | 65 |
| 2024 June | 32 | 11 | 43 |
| 2024 May | 41 | 17 | 58 |
| 2024 April | 38 | 35 | 73 |
| 2024 March | 35 | 14 | 49 |
| 2024 February | 21 | 15 | 36 |
| 2024 January | 37 | 14 | 51 |
| 2023 December | 27 | 22 | 49 |
| 2023 November | 52 | 40 | 92 |
| 2023 October | 39 | 37 | 76 |
| 2023 September | 37 | 30 | 67 |
| 2023 August | 53 | 11 | 64 |
| 2023 July | 24 | 28 | 52 |
| 2023 June | 42 | 16 | 58 |
| 2023 May | 65 | 6 | 71 |
| 2023 April | 56 | 5 | 61 |
| 2023 March | 25 | 1 | 26 |
| 2023 February | 31 | 3 | 34 |
| 2023 January | 24 | 7 | 31 |
| 2022 December | 29 | 2 | 31 |
| 2022 November | 0 | 0 | 0 |
Show all